These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 35099994)
1. In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d. Bikdeli B; Garcia DA Ann Intern Med; 2022 Feb; 175(2):JC17. PubMed ID: 35099994 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI; JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959 [TBL] [Abstract][Full Text] [Related]
3. In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d. Bikdeli B; Garcia DA Ann Intern Med; 2022 Feb; 175(2):JC16. PubMed ID: 35099997 [TBL] [Abstract][Full Text] [Related]
4. Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Di Micco P; Imbalzano E; Russo V; Attena E; Mandaliti V; Orlando L; Lombardi M; Di Micco G; Camporese G; Annunziata S; Piccinocchi G; Pacelli W; Del Guercio M Viruses; 2021 Dec; 13(12):. PubMed ID: 34960754 [TBL] [Abstract][Full Text] [Related]
5. [Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina]. Vazquez FJ; Korin J; Baldessari EM; Capparelli FJ; Gutierrez P; Pale C; Bocanegra F; Grand B; Penchasky D; Gonzalez Alcántara MM; Prémoli MS; Tabares A; Wainsztein N; Odetto D; Vaccaro C; Martínez Aquino E; Cumpian O; Falabella V; Antuel García S; Saadi J; Siccardi M; Gándara E Medicina (B Aires); 2020; 80 Suppl 3():65-66. PubMed ID: 32658849 [TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Fontana P; Casini A; Robert-Ebadi H; Glauser F; Righini M; Blondon M Swiss Med Wkly; 2020 Jun; 150():w20301. PubMed ID: 32640479 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for COVID-19 Patients: A Bird's-Eye View. Kreidieh F; Temraz S Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937 [TBL] [Abstract][Full Text] [Related]
8. [COVID-19, anticoagulation and venous thromboembolism: what have we learned ?]. Blondon M; Robert-Ebadi H Rev Med Suisse; 2021 Dec; 17(762):2140-2144. PubMed ID: 34878743 [TBL] [Abstract][Full Text] [Related]
9. Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department. Marchioni C; Esposito G; Calci M; Bais B; Colussi G BMC Emerg Med; 2022 Jun; 22(1):107. PubMed ID: 35698054 [TBL] [Abstract][Full Text] [Related]
14. In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days. Donato AA Ann Intern Med; 2021 Dec; 174(12):JC135. PubMed ID: 34871054 [TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129 [TBL] [Abstract][Full Text] [Related]
16. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? Iba T; Connors JM; Spyropoulos AC; Wada H; Levy JH Int J Hematol; 2021 Mar; 113(3):330-336. PubMed ID: 33471294 [TBL] [Abstract][Full Text] [Related]
17. An observational study of intermediate- or high-dose thromboprophylaxis for critically ill COVID-19 patients. Jonmarker S; Litorell J; Dahlberg M; Stackelberg O; Everhov ÅH; Söderberg M; Rubenson-Wahlin R; Günther M; Mårtensson J; Hollenberg J; Joelsson-Alm E; Cronhjort M Acta Anaesthesiol Scand; 2022 Mar; 66(3):365-374. PubMed ID: 34875111 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Cattaneo M; Bertinato EM; Birocchi S; Brizio C; Malavolta D; Manzoni M; Muscarella G; Orlandi M Thromb Haemost; 2020 Aug; 120(8):1230-1232. PubMed ID: 32349132 [No Abstract] [Full Text] [Related]
19. The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Di Micco P; Tufano A; Cardillo G; Imbalzano E; Amitrano M; Lodigiani C; Bellizzi A; Camporese G; Cavalli A; De Stefano C; Russo V; Voza A; Perrella A; Prandoni P Viruses; 2021 Aug; 13(9):. PubMed ID: 34578301 [TBL] [Abstract][Full Text] [Related]
20. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]